Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer.

Frontiers in immunology - 1 Jan 2023

Wang Luyao, Yang Zongxing, Guo Fucheng, Chen Yurong, Wei Jiarui, Dai Xiangpeng, Zhang Xiaoling

Abstract excerpt

Currently, anti-PD-1/PD-L1 immunotherapy using immune checkpoint inhibitors is widely used in the treatment of multiple cancer types including lung cancer, which is a leading cause of cancer death in the world. However, only a limited proportion of lung cancer patients will benefit from anti-PD-1/PD-L1 therapy. Therefore, it is of importance to predict the response to immunotherapy for the precision treatment of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Lung Neoplasms

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 37465684
DOI: 10.3389/fimmu.2023.1227797
PMCID: PMC10351040

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer.PMID 37465684Read ↗

Molecular markers related to immunosurveillance as predictive and monitoring tools in non-small cell lung cancer: recent accomplishments and future promises.Semantic proximity Read ↗

Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond.Semantic proximity Read ↗

PD-L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non-small cell lung cancer?Semantic proximity Read ↗

Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system.Semantic proximity Read ↗

Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer.Semantic proximity Read ↗

The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung CancerSemantic proximity Read ↗

PD-L1 as a biomarker in NSCLC: challenges and future directionsSemantic proximity Read ↗

[Emerging biomarker for immunotherapy of non-small cell lung cancer: tumor mutation burden (TMB) and latest progress in related research field].Semantic proximity Read ↗

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors.Semantic proximity Read ↗

Mutation mapping of PD-L1 expression in advanced non-small cell lung cancer: A real-world retrospective cohort studySemantic proximity Read ↗

Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.Semantic proximity Read ↗

Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.